



**GI & HPB ONCOSURGERY**  
**Gujarat Cancer & Research Institute**  
**AHMEDABAD, GUJARAT - INDIA**



**PANCREATIC DUCTAL ADENOCARCINOMA**




**Artery first and total mesopancreas excision**

**Orlando Jorge M. Torres**  
Department of Gastrointestinal Surgery  
Hepatopancreatobiliary and Liver Transplant Unit  
Maranhão Federal University - Brazil

## Most Pancreatic Cancer Resections are R1 Resections

2008

Irene Esposito, MD,<sup>1,3</sup> Jörg Kleeff, MD,<sup>2,4</sup> Frank Bergmann, MD,<sup>1</sup> Caroline Reiser, MD,<sup>2,4</sup>  
Esther Herpel, MD,<sup>1</sup> Helmut Friess, MD,<sup>2,4</sup> Peter Schirmacher, MD,<sup>1</sup> and  
Markus W. Büchler, MD<sup>2</sup>



Irene Esposito - Heidelberg (Germany)

## Most Pancreatic Cancer Resections are R1 Resections


Irene Esposito, MD,<sup>1,3</sup> Jörg Kleeff, MD,<sup>2,4</sup> Frank Bergmann, MD,<sup>1</sup> Caroline Reiser, MD,<sup>2,4</sup>  
Esther Herpel, MD,<sup>1</sup> Helmut Friess, MD,<sup>2,4</sup> Peter Schirmacher, MD,<sup>1</sup> and  
Markus W. Büchler, MD<sup>2</sup>

**TABLE 3.** Tumor margin characteristics of 111 consecutive macroscopic complete resections for pancreatic ductal adenocarcinoma (2005–2006)

Characteristic	Value, n (%)
R classification	
R0	27 (24%)
<b>R1</b>	<b>84 (76%)</b>
RM involvement	
Posterior	39 (47%)
<b>Medial</b>	<b>57 (68%)</b>
Anterior surface	8 (10%)
Superior	0
Transection (pancreas)	3 (4%)
Bile duct	4 (5%)
Stomach/duodenum	3 (4%)
Number of margins	
1	56 (68%)
2	22 (26%)
3 or more	5 (6%)
Type of involvement	
Direct extension	78 (93%)
Locoregional spreading	6 (7%)


RM, resection margin.

**Medial margin: Mesopancreas**




## Most Pancreatic Cancer Resections are R1 Resections

Irene Esposito, MD,<sup>1,3</sup> Jörg Kleeff, MD,<sup>2,4</sup> Frank Bergmann, MD,<sup>1</sup> Caroline Reiser, MD,<sup>2,4</sup>  
Esther Herpel, MD,<sup>1</sup> Helmut Friess, MD,<sup>2,4</sup> Peter Schirmacher, MD,<sup>1</sup> and  
Markus W. Büchler, MD<sup>2</sup>





Esposito I, et al. Ann Surg Oncol 2008; 15:1651–60

## Mesopancreas



Fernandes ESM, et al. Langenbeck's Arch Surg 2021

# Mesopancreas




Superior mesenteric vein (SMV)  
Superior mesenteric artery (SMA)

ORIGINAL ARTICLE

# Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study

**d - SMA margin clearance & disease free survival**



ORIGINAL ARTICLE

**Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study**


**Conclusion:** Local recurrence of pancreatic cancer is common and associated with similar mortality rates as those who present with simultaneous or metastatic recurrence. Involvement of the SMA margin is an independent predictor for disease progression



## Optimal Lymphadenectomy of the Mesopancreas Based on Fluorescence Imaging During Pancreaticoduodenectomy

Ryota Matsuki<sup>1</sup> · Masanori Sugiyama<sup>2</sup> · Masaharu Kogure<sup>1</sup> · Masaaki Yokoyama<sup>3</sup> · Tetsuya Nakazato<sup>1</sup> · Yutaka Suzuki<sup>1</sup> · Toshiyuki Mori<sup>1</sup> · Nobutsugu Abe<sup>1</sup> · Yoshihiro Sakamoto<sup>1</sup>

**Fig. 1** Lymphatic pathways from the pancreatic head. The first JA is taped. Fluorescence is seen in the mesentery of the IPDA and first JA (arrow), but not in that of the second JA or more distant



**Table 2** Lymphatic pathways around the mesopancreas in the patients injected with ICG

No	Time after injection of ICG (min)	Mesentery along the IPDA-J1A	Mesentery along the J2A	Mesentery along the middle colic artery	Along the SMA
1	112	○	×	×	○
2	117	○	×	×	○
3	145	○	×	×	○
4	217	○	×	×	○
5	170	○	×	×	○
6	246	○	×	×	○
7	157	○	×	×	○
8	175	×	×	×	○
9	280	○	×	×	○
10	180	○	×	×	○

○: Positive staining

×: Negative staining

ICG indocyanine green, IPDA inferior pancreaticoduodenal artery, JA jejunal artery, SMA superior mesenteric artery



# PANCREATIC CANCER

ORIGINAL SCIENTIFIC REPORT

## Complete Lymphadenectomy Around the Entire Superior Mesenteric Artery Improves Survival in Artery-First Approach Pancreatoduodenectomy for T3 Pancreatic Ductal Adenocarcinoma

<http://dx.doi.org/10.1016/j.hpb.2015.11.009>

HPB

REVIEW ARTICLE

### A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma

Journal of Surgical Oncology 2016;113:668–671

HOW I DO IT

### Top-Down Approach to the Superior Mesenteric Artery and the Mesopancreas During Pancreatoduodenectomy for Pancreatic Cancer

THILO WELSCH, MD,\* ULRICH BORK, MD, MARIUS DISTLER, MD, AND JÜRGEN WEITZ, MD

[www.impactjournals.com/oncotarget/](http://www.impactjournals.com/oncotarget/)

Oncotarget, 2017, Vol. 8, (No. 5), pp: 7766-7776

Research Paper

### Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma

Dao-ning Liu<sup>1</sup>, Ang Lv<sup>1</sup>, Zhi-hua Tian<sup>2</sup>, Xiu-yun Tian<sup>1</sup>, Xiao-ya Guan<sup>1</sup>, Bin Dong<sup>2</sup>, Min Zhao<sup>3</sup>, Chun-yi Hao<sup>1</sup>

# SUPERIOR MESENTERIC ARTERY

DOI: 10.1002/jhpb.725

ORIGINAL ARTICLE

### Precise anatomical resection based on structures of nerve and fibrous tissue around the superior mesenteric artery for mesopancreas dissection in pancreaticoduodenectomy for pancreatic cancer

Yuichi Nagakawa<sup>1</sup> | Shuang-Qin Yi<sup>2</sup> | Chie Takishita<sup>1</sup> | Yatsuka Sahara<sup>1</sup> |

Surgical Endoscopy  
<https://doi.org/10.1007/s00464-019-06994-6>

DYNAMIC MANUSCRIPT

### Follow “the superior mesenteric artery”: laparoscopic approach for total mesopancreas excision during pancreaticoduodenectomy

Edouardo Morales<sup>1</sup> · Giuseppe Zimmitti<sup>1</sup> · Claudio Codignola<sup>1</sup> · Alberto Manzoni<sup>1</sup> · Marco Garatti<sup>1</sup> · Valentina Segà<sup>1</sup> · Edoardo Rosso<sup>1</sup>

Anatomical Science International  
<https://doi.org/10.1007/s12565-020-00597-1>

ORIGINAL ARTICLE

### What comprises the plate-like structure between the pancreatic head and the celiac trunk and superior mesenteric artery? A proposal for the term “P–A ligament” based on anatomical findings

Satoru Muro<sup>1</sup> · Wachirawit Sirirat<sup>1</sup> · Daisuke Ban<sup>2</sup> · Yuichi Nagakawa<sup>3</sup> · Keiichi Akita<sup>1</sup>

J Gastrointest Surg (2014) 18:1209–1215  
DOI 10.1007/s11605-014-2495-3

HOW I DO IT

### Anterior Approach to the Superior Mesenteric Artery by Using Nerve Plexus Hanging Maneuver for Borderline Resectable Pancreatic Head Carcinoma

Shugo Mizuno · Shuji Isaji · Akihiro Tanemura · Masashi Kishiwada ·

Journal of Gastrointestinal Surgery  
<https://doi.org/10.1007/s11605-018-3995-3>

ORIGINAL ARTICLE

### Optimal Extent of Superior Mesenteric Artery Dissection during Pancreatoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety

Yosuke Inoue<sup>1</sup> · Akio Saiura<sup>1</sup> · Atsushi Oba<sup>1</sup> · Shoji Kawakatsu<sup>1</sup> · Yoshihiro Ono<sup>1</sup> · Takafumi Sato<sup>1</sup> · Yoshihiro Mise<sup>1</sup> ·

EDIAN WING 2013.11.27 13:56:13 Page 2(1)  
y o i n W P S / 2 2 5 1 1 - 3 6 8 2 / n i d e 0 6 - 0 7 / k y o 1 7 5 3 1 3 6 8 2 0 0 4 5 2 4 6

—Report on Experiments and Clinical Cases—

### Left Posterior Approach Pancreatoduodenectomy with Total Mesopancreas Excision and Circumferential Lymphadenectomy Around the Superior Mesenteric Artery for Pancreatic Head Carcinoma

Takayuki Aimoto<sup>1</sup>, Satoshi Mizutani<sup>1</sup>, Youichi Kawano<sup>1</sup>, Akira Matsushita<sup>1</sup>, Naoyuki Yamashita<sup>1</sup>, Hideyuki Suzuki<sup>1</sup> and Eiji Uchida<sup>1</sup>

International Journal of Surgery 73 (2020) 14–24

Contents lists available at ScienceDirect

International Journal of Surgery

journal homepage: [www.elsevier.com/locate/ijso](http://www.elsevier.com/locate/ijso)



Review


### Superior mesenteric artery first approach can improve the clinical outcomes of pancreaticoduodenectomy: A meta-analysis




## A more radical perspective on surgical approach and outcomes in pancreatic cancer—a narrative review

Eduardo de Souza M. Fernandes<sup>1,2,3</sup>, Felipe Pedreira T. de Mello<sup>1,2</sup>, Eduardo Pinho Braga<sup>1</sup>, Gabrielle Oliveira de Souza<sup>1</sup>, Ronaldo Andrade<sup>1,2</sup>, Leandro Savatone Pimentel<sup>1,2</sup>, Camila Liberato Girão<sup>1,2</sup>, Munique Siqueira<sup>1,2</sup>, José Maria A. Moraes-Junior<sup>6,7</sup>, Romulo Varela de Oliveira<sup>4</sup>, Nicolas Goldaracena<sup>5</sup>, Orlando Jorge M. Torres<sup>6,7</sup>

# ARTERY FIRST



# ARTERY FIRST



Superior mesenteric artery

Left renal vein

Aorta


Inferior vena cava (IVC)

Duodenum

POSTERIOR APPROACH

# ARTERY FIRST


Superior mesenteric artery



Left renal vein


POSTERIOR APPROACH

# ARTERY FIRST




Inferior pancreaticoduodenal artery (IPDA)

Pandanaboyana S, et al. Br J Surg 2012;99:1027-




Superior mesenteric artery (SMA)



UNCINATE FIRST


# ARTERY FIRST



Superior mesenteric artery (SMA)


**UNCINATE FIRST**

# MESOPANCREAS




## FIRST JEJUNAL ARTERY






# Posterior approach



# FIRST JEJUNAL ARTERY



## The Mesenteric Approach in Pancreatoduodenectomy




**MESENTERIC APPROACH**


# A more radical perspective on surgical approach and outcomes in pancreatic cancer—a narrative review

## MESENTERIC APPROACH


Eduardo de Souza M. Fernandes<sup>1,2,3</sup>, Felipe Pedreira T. de Mello<sup>1,2</sup>, Eduardo Pinho Braga<sup>1</sup>, Gabrielle Oliveira de Souza<sup>1</sup>, Ronaldo Andrade<sup>1,2</sup>, Leandro Savatone Pimentel<sup>1,2</sup>, Camila Liberato Girão<sup>1,2</sup>, Munique Siqueira<sup>1,2</sup>, José Maria A. Moraes-Junior<sup>6,7</sup>, Romulo Varella de Oliveira<sup>4</sup>, Nicolas Goldaracena<sup>5</sup>, Orlando Jorge M. Torres<sup>6,7</sup>

Inferior pancreatoduodenal artery (IPDA)







**Infracolic approach**



**MESENTERIC APPROACH**

## INFRACOLIC APPROACH





## MESENTERIC APPROACH

# Classification of Pancreatic Carcinoma



Japan Pancreas Society  
Fourth English Edition

Kanehara & Co., Ltd.






## The mesopancreas and pancreatic head plexus: morphological, developmental, and clinical perspectives



# TOTAL MESOPANCREAS EXCISION



## MESOPANCREAS

- pIph-I
- pIph-II
- IPDA
- Jejunal arteries
- Jejunal veins
- Lymph nodes



# ARTERIES


# INFERIOR PANCREATODUODENAL ARTERY (IPDA)



# Common trunk

# EPICENTER OF THE PANCREATODUODENECTOMY

**IPDA**




Superior mesenteric artery




**UNCINATE FIRST**

Inferior pancreatoduodenal artery



## What do surgeons need to know about the mesopancreas

Eduardo de Souza M. Fernandes<sup>1,2</sup> · Oliver Strobel<sup>3,4</sup> · Camila Girão<sup>1,2</sup> · Jose Maria A. Moraes-Junior<sup>5,6</sup> · Orlando Jorge M. Torres<sup>5,6</sup> 




**PANCREATIC HEAD PLEXUS (PL ph)**

## ADVANTAGES OF ARTERY FIRST APPROACH

**Table 3** Advantages of the artery-first approach (SHARMA) [35]

1. Resection without breaching the tumor extension plane, thereby minimizing cell spillage
2. Increases curative (R0) resection, decreases local recurrence
3. Complete resection of peripancreatic retroperitoneal tissue around the plexuses
4. Increased lymph nodal clearance
5. Early assessment of non-resectability (SMA involvement), avoiding useless R2 resections
6. Better delineation of SMA and identification of RHA anomalies
7. Easier en bloc resection and reconstruction of SMV-PV by “no touch” technique
8. Reduced need for graft substitutions
9. Reduced operative time and blood loss (early ligation of IPDA/JA1)

**Superior mesenteric artery**




Portal vein involvement

The SMA is free

Superior mesenteric artery

**UNCINATE FIRST**

**ARTERY FIRST**



**IPDA**

**Right margin of SMA  
(5 o'clock - 11 o'clock)**

**UNCINATE FIRST**

## ADVANTAGES OF ARTERY FIRST APPROACH

**Table 3** Advantages of the artery-first approach (SHARMA) [35]

- 
1. Resection without breaching the tumor extension plane, thereby minimizing cell spillage
  2. Increases curative (R0) resection, decreases local recurrence
  3. Complete resection of peripancreatic retroperitoneal tissue around the plexuses
  4. Increased lymph nodal clearance
  5. Early assessment of non-resectability (SMA involvement), avoiding useless R2 resections
  6. Better delineation of SMA and identification of RHA anomalies
  7. Easier en bloc resection and reconstruction of SMV-PV by “no touch” technique
  8. Reduced need for graft substitutions
  9. Reduced operative time and blood loss (early ligation of IPDA/JA1)
- 

**ARTERY FIRST**



Contents lists available at ScienceDirect

International Journal of Surgery

journal homepage: [www.elsevier.com/locate/ijss](http://www.elsevier.com/locate/ijss)



Review


Superior mesenteric artery first approach can improve the clinical outcomes of pancreaticoduodenectomy: A meta-analysis




- Higher R0 resection rate ( $p < 0.001$ )
- Lower local recurrence rate ( $p < 0.0001$ )
- Higher overall survival:
  - 1-year  $p=0.015$
  - 2-year  $p=0.005$
  - 3-year  $p=0.001$

Meta-analysis - 18 studies

## Complete Lymphadenectomy Around the Entire Superior Mesenteric Artery Improves Survival in Artery-First Approach Pancreatoduodenectomy for T3 Pancreatic Ductal Adenocarcinoma



**Fig. 1** Overall survival according to recurrence around the SMA. The median survival was 23.6 months in patients with recurrence around the SMA and 26 months in patients without recurrence around the SMA ( $p = 0.0367$ ) SMA: superior mesenteric artery



**Fig. 2** Overall survival according to the type of the surgery. The median survival was 40.3 months in the AFA-PD group and 22.6 months in the conventional PD group ( $p = 0.005$ ) AFA-PD: artery-first approach pancreatoduodenectomy

40.3 months vs 22.6 months ( $p = 0.005$ )

OVERALL SURVIVAL

## ADVANTAGES OF ARTERY FIRST APPROACH


**Table 3** Advantages of the artery-first approach (SHARMA) [35]

- 
1. Resection without breaching the tumor extension plane, thereby minimizing cell spillage
  2. Increases curative (R0) resection, decreases local recurrence
  3. Complete resection of peripancreatic retroperitoneal tissue around the plexuses
  4. Increased lymph nodal clearance
  5. Early assessment of non-resectability (SMA involvement), avoiding useless R2 resections
  6. Better delineation of SMA and identification of RHA anomalies
  7. Easier en bloc resection and reconstruction of SMV-PV by “no touch” technique
  8. Reduced need for graft substitutions
  9. Reduced operative time and blood loss (early ligation of IPDA/JA1)
- 


PANCREATIC HEAD PLEXUS (PL ph)

ARTERY FIRST

# TOTAL MESOPANCREAS EXCISION




**1. CIRCUMFERENTIAL DISSECTION OF SMV/PV**



# TOTAL MESOPANCREAS EXCISION

□ Common hepatic artery lymph nodes 8a, 8p





**2. HEMICIRCUMFERENTIAL DISSECTION OF CHA**

# COMMON HEPATIC ARTERY LYMPH NODES

□ 8a

□ 8p


A




# CELIAC TRUNK LYMPH NODES

□ Celiac trunk lymph nodes 9



A




□ 9



# TOTAL MESOPANCREAS EXCISION






## 3. HEMICIRCUMFERENTIAL DISSECTION OF SMA



# SUPERIOR MESENTERIC ARTERY LYMPH NODES


□14p

□14d





ORIGINAL ARTICLE


**The TRIANGLE operation – radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study**



# TRIANGLE OPERATION



**ADVANTAGES OF ARTERY FIRST APPROACH**




**TOTAL MESOPANCREAS EXCISION**

**Portal vein resection**

**TRIANGLE OPERATION**

**ADVANTAGES OF ARTERY FIRST APPROACH**





**TOTAL MESOPANCREAS EXCISION**

**Portal vein resection**

**TRIANGLE OPERATION**


# TRIANGLE OPERATION



# TRIANGLE OPERATION


**A**

**Recurrence-free survival**



**B**

**Overall survival**



REVIEW ARTICLE

**A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma**

James R. Butler<sup>1</sup>, Syed A. Ahmad<sup>2</sup>, Matthew H. Katz<sup>3</sup>, Jessica L. Cioffi<sup>1</sup> & Nicholas J. Zyromski<sup>1</sup>

<sup>1</sup>Indiana University School of Medicine, Department of Surgery, Indianapolis IN, <sup>2</sup>The University of Cincinnati Cancer Institute, Cincinnati OH, and <sup>3</sup>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

- R0 resection 16–79%**
- SMA most often positive (15–45%)**
- Positive margin was associated with decreased survival.**

**Conclusions:** Margin positivity in resectable pancreatic adenocarcinoma is associated with poor survival. Inability to clear the SMA margin is the most common cause of incomplete resection.

# STATE OF THE ART

## Pancreatoduodenectomy

Total mesopancreas excision'  
“Artery first”<sup>2</sup>


Level 3 dissection<sup>3</sup>

“Triangle operation”<sup>4</sup>

Extended resection<sup>5</sup>

+/- portal/SM vein

Liver metastasis



1. Fernandes ES, et al. Langenbecks Arch Surg 2021

2. Inoue Y, et al. J Gastrointest Surg 2018

3. Niesen W, et al. Ann Gastroenterol Surg. 2019

4. Hackert T, et al. HPB 2017

5. Fernandes ES, et al. J Gastrointest Oncol 2023

6. Torres OJ, Zurich and Cape Town

## ADVANTAGES OF ARTERY FIRST APPROACH

**Table 3** Advantages of the artery-first approach (SHARMA) [35]

- 
1. Resection without breaching the tumor extension plane, thereby minimizing cell spillage
  2. Increases curative (R0) resection, decreases local recurrence
  3. Complete resection of peripancreatic retroperitoneal tissue around the plexuses
  4. Increased lymph nodal clearance
  5. Early assessment of non-resectability (SMA involvement), avoiding useless R2 resections
  6. Better delineation of SMA and identification of RHA anomalies
  7. Easier en bloc resection and reconstruction of SMV-PV by “no touch” technique
  8. Reduced need for graft substitutions
  9. Reduced operative time and blood loss (early ligation of IPDA/JA1)
- 

**ARTERY FIRST**

# LYMPHATICS

## Lymph node stations pancreatic cancer

□ Hepatoduodenal ligament  
12a, 12b1, 12b2, 12p, 12c


□ Common hepatic artery 8a, 8p

□ Celiac trunk lymph nodes 9



□ Pyloric 5, 6

□ Superior mesenteric artery 14p, 14d

□ Pancreatoduodenal (anterior and posterior)  
13a, 13b, 17a, 17b





# LYMPHADENECTOMY



14p, 14d

# LYMPHADENECTOMY





## Complete Lymphadenectomy Around the Entire Superior Mesenteric Artery Improves Survival in Artery-First Approach Pancreatoduodenectomy for T3 Pancreatic Ductal Adenocarcinoma

### ARTERY FIRST

**Table 2** Comparison of perioperative and oncological outcomes between the AFA-PD group and the conventional PD group

	AFA-PD group	Conventional PD group	<i>P</i>
	<i>n</i> = 45	<i>n</i> = 43	
Operative time, median (range), min	443 (390–497)	467 (414–530)	0.1312
Intraoperative blood loss, median (range), mL	811 (520–1150)	899 (720–1443)	<b>0.0210</b>
Transfusion, <i>n</i> (%)	19 (42.2)	22 (51.2)	0.5178
Portal vein resection, <i>n</i> (%)	12 (26.7)	13 (30.2)	0.8147
Postoperative complications, $\geq$ grade IIIa, <i>n</i> (%)	3 (6.7)	5 (11.6)	0.4794
Curative resection R0, <i>n</i> (%)	35 (77.8)	28 (65.1)	0.3423
No. harvested lymph nodes, median (range)	23 (14–37)	19 (12–22)	<b>0.0165</b>
No. harvested lymph nodes of #14p, median (range)	4 (2–5)	1 (0–3)	<b>&lt; 0.001</b>
No. harvested lymph nodes of #14d, median (range)	4 (2–5)	2 (0–3)	<b>0.0146</b>
Lymph node metastasis, <i>n</i> (%)	27 (60)	30 (69.8)	0.3376

Bold values are statistically significant ( $p < 0.05$ )


AFA-PD - Artery first approach pancreatoduodenectomy

## ADVANTAGES OF ARTERY FIRST APPROACH



**Table 3** Advantages of the artery-first approach (SHARMA) [35]

- 
1. Resection without breaching the tumor extension plane, thereby minimizing cell spillage
  2. Increases curative (R0) resection, decreases local recurrence
  3. Complete resection of peripancreatic retroperitoneal tissue around the plexuses
  4. Increased lymph nodal clearance
  5. Early assessment of non-resectability (SMA involvement), avoiding useless R2 resections
  6. Better delineation of SMA and identification of RHA anomalies
  7. Easier en bloc resection and reconstruction of SMV-PV by “no touch” technique
  8. Reduced need for graft substitutions
  9. Reduced operative time and blood loss (early ligation of IPDA/JA1)
- 

**ARTERY FIRST**



**SMA INVOLVEMENT**




**MESENTERIC APPROACH**

## ADVANTAGES OF ARTERY FIRST APPROACH

**Table 3** Advantages of the artery-first approach (SHARMA) [35]


- 
1. Resection without breaching the tumor extension plane, thereby minimizing cell spillage
  2. Increases curative (R0) resection, decreases local recurrence
  3. Complete resection of peripancreatic retroperitoneal tissue around the plexuses
  4. Increased lymph nodal clearance
  5. Early assessment of non-resectability (SMA involvement), avoiding useless R2 resections
  6. Better delineation of SMA and identification of RHA anomalies
  7. Easier en bloc resection and reconstruction of SMV-PV by “no touch” technique
  8. Reduced need for graft substitutions
  9. Reduced operative time and blood loss (early ligation of IPDA/JA1)
- 

**ARTERY FIRST**





Right hepatic artery


Superior mesenteric artery



ARTERY FIRST





**HEPATIC ARTERY**





**SUPERIOR MESENTERIC ARTERY**

**Table 3** Advantages of the artery-first approach (SHARMA) [35]


- 
1. Resection without breaching the tumor extension plane, thereby minimizing cell spillage
  2. Increases curative (R0) resection, decreases local recurrence
  3. Complete resection of peripancreatic retroperitoneal tissue around the plexuses
  4. Increased lymph nodal clearance
  5. Early assessment of non-resectability (SMA involvement), avoiding useless R2 resections
  6. Better delineation of SMA and identification of RHA anomalies
  7. Easier en bloc resection and reconstruction of SMV-PV by “no touch” technique
  8. Reduced need for graft substitutions
  9. Reduced operative time and blood loss (early ligation of IPDA/JA1)
-








Portal vein anastomosis

Portal vein/superior mesenteric vein resection/reconstruction





**Portal vein/superior mesenteric vein resection/reconstruction**




**Portal vein/superior mesenteric vein resection/reconstruction**


## ADVANTAGES OF ARTERY FIRST APPROACH

**Table 3** Advantages of the artery-first approach (SHARMA) [35]


1. Resection without breaching the tumor extension plane, thereby minimizing cell spillage
2. Increases curative (R0) resection, decreases local recurrence
3. Complete resection of peripancreatic retroperitoneal tissue around the plexuses
4. Increased lymph nodal clearance
5. Early assessment of non-resectability (SMA involvement), avoiding useless R2 resections
6. Better delineation of SMA and identification of RHA anomalies
7. Easier en bloc resection and reconstruction of SMV-PV by “no touch” technique
8. Reduced need for graft substitutions
9. Reduced operative time and blood loss (early ligation of IPDA/JA1)





**NO GRAFT**




**ARTERY FIRST**




**Portal vein/superior mesenteric vein resection/reconstruction**




**Portal vein/superior mesenteric vein resection/reconstruction**






**Portal vein/superior mesenteric vein resection/reconstruction**





**NO GRAFT**




**Table 3** Advantages of the artery-first approach (SHARMA) [35]

- 
1. Resection without breaching the tumor extension plane, thereby minimizing cell spillage
  2. Increases curative (R0) resection, decreases local recurrence
  3. Complete resection of peripancreatic retroperitoneal tissue around the plexuses
  4. Increased lymph nodal clearance
  5. Early assessment of non-resectability (SMA involvement), avoiding useless R2 resections
  6. Better delineation of SMA and identification of RHA anomalies
  7. Easier en bloc resection and reconstruction of SMV-PV by “no touch” technique
  8. Reduced need for graft substitutions
  9. Reduced operative time and blood loss (early ligation of IPDA/JA1)
- 


**MENOR TEMPO OPERATÓRIO**

# CENTRAL VASCULAR LIGATION




- Bleeding
- Pancreatic fistula
- Delayed gastric emptying
- Oncology

# ARTERY FIRST




# ARTERIAL CONTROL




# UNCINATE FIRST

## VENOUS CONTROL



**PORTAL VEIN**



**SUPERIOR MESENTERIC VEIN**

# DIVESTMENT

A) Grade 0 (No tumor)

B) Grade I (Invasion of the tunica adventitia).  
Tumor free distance from external elastic lamina  $\geq 1$ mm.


**R0 – Periarterial divestment**

C) Grade II (Tumor invasion of the tunica adventitia  $< 1$ mm of the external elastic lamina).


**R1 – Sub-adventitial divestment  
Or  
Arterial resection**

D) Grade III (Tumor invasion of the external elastic lamina).


**Arterial resection  
Or  
Case unresectable**




# DIVESTMENT



# DIVESTMENT





## Lençóis Maranhenses



[www.drorlandotorres.com.br](http://www.drorlandotorres.com.br)

Thanks!

 [orlandotorres\\_gastrocirurgia](https://www.instagram.com/orlandotorres_gastrocirurgia)



**36º CONGRESSO BRASILEIRO DE**  
**CIRURGIA**  
**CBC - RIO DE JANEIRO-RJ**  
**07 A 10 DE AGOSTO DE 2025**

Realização:

